EVERY Financial Model
Biotech/Pharma Startup Financials (Free Excel Download)
Precision fermentation company producing real animal proteins (egg proteins, pepsin) without animals, targeting food ingredients market.
professionals from Deloitte
Used by professionals from
About this model
EVERY uses engineered yeast and precision fermentation to make animal proteins without animals. Its products are animal-free pepsin and egg proteins; the latter can provide emulsification, gelling, aeration, binding, whipping, and other functions that are difficult to replace with plant proteins.
The company sells ingredients to food manufacturers and buyers, pursuing premium pricing for superior functionality before eventually undercutting animal-protein costs. Conventional egg trace proteins can cost more than $10,000 per kilogram. The operating model is described as lean and partner-driven, implying contract manufacturing or white-label scale-up rather than wholly owned production.
Animal-free pepsin was already selling across three continents, while the platform was moving from pilot toward commercial scale. No customer count, price per kilogram, volume, revenue, or contract terms are disclosed. The model should forecast approvals, capacity, ingredient volume, price, manufacturing cost, customer contracts, and scale-up capex.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
About EVERY
every.tech
How to build a detailed financial model for EVERY
A complete walkthrough of the business, drivers, and assumptions behind the downloadable EVERY model - distilled from its pitch deck and publicly available information.
Product & value proposition
- Platform: Precision fermentation using engineered yeast to brew real animal proteins from DNA blueprints, without the animal.
- Product 1 - Animal-free pepsin: World's first. Selling across three continents. Greater purity & higher activity than animal-derived. Certified Kosher, halal, vegan, vegetarian.
- Product 2 - Animal-free egg protein: World's first. Unlocks trace proteins (<1% of the egg) infeasible to extract from nature. Enhanced solubility vs. soy, pea, whey, egg white. Target proteins traditionally cost $10,000+ per kg using eggs.
- Egg proteins deliver 20+ critical functionalities (emulsification, gelling, aeration, binding, whipping, leavening, coagulation, etc.) making them hard to replace - that is the supply-side moat.
- Core thesis: Same proteins, better (animal-free, lower-cost) production path. Enables premium positioning AND eventual cost undercut of conventional animal protein.
Market
- TAM stated as "$200B+ market opportunity".
- No SAM or SOM breakdowns provided.
- No CAGR or growth rate cited.
- Addressable segments implied: food ingredients, functional ingredients, nutraceuticals/pharma (pepsin), baked goods, condiments, pasta, confectionery (egg-based products).
Revenue model
- B2B ingredient sales: sell precision-fermented proteins (powder form implied) to food manufacturers and ingredient buyers.
- Pricing strategy: "Sustained, premium pricing opportunities" from product hyper-functionality; long-term goal to "undercut mass animal protein market" via industry-low production costs.
- Reference price point: conventional egg trace proteins cost $10,000+ per kg - EVERY's value proposition is producing these at lower cost.
- Partner-driven model: "Lean, partner-driven model - focus on core while reducing execution risk". Suggests contract manufacturing / white-label partnerships rather than in-house scale-up.
- No pricing per kg, minimum order quantities, or contract structures disclosed.
Traction & metrics
- Pepsin product: selling across three continents.
- No revenue figures, customer counts, ARR/MRR, unit volumes, or growth rates shown in the deck.
- Stage described as demonstrating "platform scalability from Pilot → Commercial".
Competition / moat
- Competitive positioning (implied from deck):
- Conventional animal egg proteins: expensive ($10,000+/kg for trace proteins), animal welfare / supply-chain risk.
- Plant-based substitutes (soy, pea): inferior solubility and functionality vs. EVERY.
- Moat claims: proprietary DNA blueprints → yeast fermentation; 20+ functional attributes hard to replicate with plant protein; certifications (Kosher, halal, vegan) open markets conventional egg proteins cannot address.
- No named competitors discussed.
Team & funding ask / use of funds
Recommended financial model
- Archetype + why: B2B specialty ingredient revenue model (volume × price per kg, by product line). EVERY is a biotech ingredient company at early commercial stage - appropriate archetype is a multi-product B2B revenue build with COGS driven by fermentation yield and batch economics, scaling toward gross margin expansion. Not a SaaS or marketplace model.
- Forecast horizon & granularity: 5 years (2024–2028), quarterly for years 1–2, annual for years 3–5. Early-stage company needs quarterly visibility to bridge from pilot to commercial scale.
- Key drivers & assumptions:
| Driver | Value |
|---|---|
| Products modelled | Pepsin (launched), Egg protein (pipeline) |
| TAM | $200B+ (total animal protein ingredient market) |
| Pepsin launch geography | 3 continents |
| Pepsin ASP ($/kg) | To be confirmed - reference: animal-derived pepsin market rate |
| Egg protein ASP ($/kg) | Meaningful discount to $10,000/kg conventional trace protein; premium to commodity egg white powder |
| Annual volume growth rate | 80–150% in early years (pilot to commercial ramp) |
| Gross margin (near-term) | 40–55% at commercial scale |
| COGS per kg | Fermentation yield, yeast media, downstream processing, CMO fees |
| R&D spend | Elevated as % of revenue in years 1–2, declining to ~20% by year 5 |
| Headcount / OpEx | Lean model; G&A ~15–20% of revenue - "lean, partner-driven" language |
| Capital intensity | Low relative to vertically integrated fermentation; CAPEX largely with CMO partners |
| New protein line launches | 1 additional protein per 18–24 months |
- Scenarios (Base / Bull / Bear - which variables flex):
- Base: Pepsin scales commercially by end of year 1; egg protein commercial launch year 2; gross margin reaches 50% by year 3.
- Bull: Faster regulatory clearance; additional protein lines launch earlier; premium ASP sustained as category leader.
- Bear: Fermentation yield targets missed; CMO partner delays; commodity egg prices fall (reducing EVERY's cost advantage); slower customer adoption.
- Flex variables: volume ramp (kg/year), ASP ($/kg), gross margin %, R&D timeline for new proteins, number of commercial partnerships.
- Required sheets / outputs:
- Assumptions dashboard (toggle Base/Bull/Bear)
- Revenue build - by product line × region × volume × ASP
- COGS build - fermentation batch economics (yield, media cost, downstream), CMO fee structure
- P&L (Income Statement) - gross margin, R&D, S&M, G&A, EBITDA
- Cash burn / runway - pre-revenue burn, cash-to-milestones
- KPI summary - kg sold, ASP, gross margin %, revenue per product
- (Optional) Sensitivity table - gross margin vs. ASP and yield
Frequently asked
Is the EVERY financial model free?+
Yes. The EVERY model is a free Excel (.xlsx) download with live formulas. Sign up with your email and the workbook is yours to keep, review, and edit.
What's included in the model?+
A 5-year monthly forecast with P&L, cash flow and runway, valuation (exit multiple plus a DCF cross-check), MOIC/IRR returns, and unit economics, with live formulas throughout.
How was this model built?+
It was built from EVERY's pitch deck and publicly available information, then structured to investment-banking standards as a fully editable Excel model.
Can I change the assumptions?+
Yes. You can change assumptions and the live formulas will recalculate in the downloadable Excel model.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Biotech/Pharma Startup Financial Models
Browse another startup in the same category.
Ada Health
AI-powered symptom assessment app and clinical decision-support platform for consumers and healthcare partners.
Affini-T
Engineered T cell therapies targeting oncogenic driver mutations (KRAS, p53) in hard-to-treat solid tumors
Alto Pharmacy
Alto Pharmacy is a tech-enabled, same-day prescription delivery pharmacy disrupting the $450B US pharmacy market via a direct-to-patient courier model and provider-facing software platform.
Aphea.Bio
Aphea.Bio is a Belgian ag-biotech company developing and commercialising microbial biologicals (biostimulants, biofungicides, bioherbicides, bioinsecticides) for row crops, targeting yield improvement and reduced synthetic input use.
Aurion Biotech
Cell therapy company developing an injectable corneal endothelial cell treatment to restore vision in patients with corneal endothelial disease.
Beckley Psytech
Clinical-stage psychedelic drug development platform advancing a pipeline of psychedelic compounds (psilocybin, 5-MeO-DMT, NCEs) as licensed pharmaceutical medicines for neuropsychiatric disorders.
BrightInsight
Regulated digital health platform-as-a-service for biopharma and medtech companies to build, launch, and maintain compliant connected-drug and medical-device software products.
Carrum Health
Value-based care marketplace connecting self-insured employers to top-tier surgical and oncology Centers of Excellence (COEs) via all-inclusive bundled payments.
